India cancels China procurement orders as test kits received test "faulty"

29 April 2020
lab-testing-big

Efforts by an Indian agency to procure rapid antibody coronavirus test kits from China have come to naught, with the Indian government deciding to withdraw the "faulty" test kits from use and cancelling all procurement orders. The controversy around the efficacy and pricing of the rapid tests is set to change the way India now tests for the novel coronavirus.

On April 16, India received 500,000 rapid antibody testing kits from China, with the Indian Council of Medical Research (ICMR) stating they would be used for understanding the coronavirus disease and not for diagnosing the infection.

On April 27, the ICMR sent out advisories to state governments to stop the use of kits. Multiple states claimed the rapid testing kits were showing inaccurate results. The Indian government has since cancelled its order.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical